Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients.

Gately S.

Cancer Treat Res. 2019;178:253-264. doi: 10.1007/978-3-030-16391-4_10.

PMID:
31209849
2.

Synthesis of improved lysomotropic autophagy inhibitors.

Wang T, Goodall ML, Gonzales P, Sepulveda M, Martin KR, Gately S, MacKeigan JP.

J Med Chem. 2015 Apr 9;58(7):3025-35. doi: 10.1021/jm501586m. Epub 2015 Mar 27.

PMID:
25793774
3.

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.

Goodall ML, Wang T, Martin KR, Kortus MG, Kauffman AL, Trent JM, Gately S, MacKeigan JP.

Autophagy. 2014 Jun;10(6):1120-36. doi: 10.4161/auto.28594.

4.

Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.

Wang T, Sepulveda M, Gonzales P, Gately S.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4790-3. doi: 10.1016/j.bmcl.2013.07.001. Epub 2013 Jul 10.

PMID:
23906422
5.

A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression.

Levine TD, Bowser R, Hank NC, Gately S, Stephan D, Saperstein DS, Van Keuren-Jensen K.

Neurol Res Int. 2012;2012:582075. doi: 10.1155/2012/582075. Epub 2012 Jun 28.

6.

Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.

Demeure MJ, Stephan E, Sinari S, Mount D, Gately S, Gonzales P, Hostetter G, Komorowski R, Kiefer J, Grant CS, Han H, Von Hoff DD, Bussey KJ.

Ann Surg. 2012 Jan;255(1):140-6. doi: 10.1097/SLA.0b013e3182402d21.

PMID:
22156929
7.

The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.

Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET.

BMC Cancer. 2011 Nov 2;11:471. doi: 10.1186/1471-2407-11-471.

8.

β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.

Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I, Dunckley T.

PLoS One. 2011 May 6;6(5):e19264. doi: 10.1371/journal.pone.0019264.

9.

Targeting cyclooxygenase-2 for cancer prevention and treatment.

Gately ST.

Prog Drug Res. 2005;63:207-25. Review. No abstract available.

PMID:
16265882
10.

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

Gately S, Li WW.

Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11. Review.

PMID:
15179620
11.
12.

Tumor production of angiostatin is enhanced after exposure to TNF-alpha.

Mauceri HJ, Seetharam S, Beckett MA, Lee JY, Gupta VK, Gately S, Stack MS, Brown CK, Swedberg K, Kufe DW, Weichselbaum RR.

Int J Cancer. 2002 Feb 1;97(4):410-5.

13.

Antiangiogenic scheduling of lower dose cancer chemotherapy.

Gately S, Kerbel R.

Cancer J. 2001 Sep-Oct;7(5):427-36. Review.

PMID:
11693902
14.

The contributions of cyclooxygenase-2 to tumor angiogenesis.

Gately S.

Cancer Metastasis Rev. 2000;19(1-2):19-27. Review.

PMID:
11191059
15.

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA.

Biochem J. 1999 May 15;340 ( Pt 1):77-84.

16.

Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.

Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR.

Cancer Res. 1998 Dec 15;58(24):5686-9.

17.

Combined effects of angiostatin and ionizing radiation in antitumour therapy.

Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR.

Nature. 1998 Jul 16;394(6690):287-91.

PMID:
9685160
18.

Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.

Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS.

Cancer Res. 1997 Dec 1;57(23):5277-80.

20.

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10868-72.

21.

Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.

Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA.

Cancer Res. 1996 Nov 1;56(21):4887-90.

24.

Cells transfected with the basic fibroblast growth factor gene fused to a signal sequence are invasive in vitro and in situ in the brain.

Gately S, Tsanaclis AM, Takano S, Klagsbrun M, Brem S.

Neurosurgery. 1995 Apr;36(4):780-8.

PMID:
7596510
25.

A diaminoantraquinone inhibitor of angiogenesis.

Takano S, Gately S, Jiang JB, Brem S.

J Pharmacol Exp Ther. 1994 Nov;271(2):1027-33.

PMID:
7525934
26.

Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.

Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S.

Cancer Res. 1994 May 15;54(10):2654-60.

27.

Suramin inhibits glioma cell proliferation in vitro and in the brain.

Takano S, Gately S, Engelhard H, Tsanaclis AM, Brem S.

J Neurooncol. 1994;21(3):189-201.

PMID:
7699415
28.

Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors.

Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF.

Cancer. 1992 Dec 1;70(11):2673-80.

PMID:
1423198
29.

Statin immunolocalization in human brain tumors. Detection of noncycling cells using a novel marker of cell quiescence.

Tsanaclis AM, Brem SS, Gately S, Schipper HM, Wang E.

Cancer. 1991 Aug 15;68(4):786-92.

PMID:
1855178
30.

Supplemental Content

Loading ...
Support Center